Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology.
Our peer-reviewed research, featured recently in healthcare and mainstream news reports.
This sweeping proposal is the biggest step yet in shifting reimbursement from a volume-based to a value-based system. Stakeholders offered mixed opinions this week.
What We’re Reading, April 29, 2016: While sales of Gilead's Harvoni drop, NY state attorney's decision could be good news for the company; and the FDA faces a lawsuit from a consumer advocacy group.
Overall use of a web-based tool providing real-time, personalized episode-level price estimates for healthcare was low, but for some procedures the number of people searching for prices of services was high relative to the number of people who received the service.
A small study in 30 patients with advanced B-cell acute lymphoblastic leukemia has further strengthened the faith in the potential of chimeric antigen receptor or CAR-T cell therapy.
Unlike its closest rival, CVS Health, Express Scripts does not have a retail healthcare delivery infrastructure.
One leading expert called the proposal the most substantive change in decades, but some feared CMS is once again hastening the demise of the independent physician.
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
HF Compendium